Efficacy of alemtuzumab treatment in active relapsing remitting multiple sclerosis : A study of real world evidence

---

Mentor: Dr. Ofir Zmira

Student: Alex Halpern

Multiple Sclerosis

Alemtuzumab

- Monoclonal Anti CD-52 antibody



https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286943/

Previous Studies



No. at Risk							
Interferon beta-1a	111	99	94	82	75	71	66
Alemtuzumab, 12 mg/day	112	107	104	101	100	96	93
Alemtuzumab, 24 mg/day	110	108	105	105	102	100	96



No. at Risk							
Interferon beta-1a	111	100	91	83	73	71	68
Alemtuzumab, 12 mg/day	112	107	103	99	99	92	88
Alemtuzumab, 24 mg/day	110	108	105	105	101	97	89

Citation: N Engl J Med 2008; 359:1786-1801

Study Design

- Prospective cohort of 35 ARRMS patients
- Variables followed:
- 1. EDSS
- 2. Relapse rate
- 3. Number and volume of MRI lesions



Results


Mean annualized relapse rate before and after initiation of alemtuzumab treatment
ARR
4
3
2
1
0
1.63
2.06
0.54
p=0.0001
2 years before treatment
1 year before treatment
2 years after beginning of treatment

Results

Neurological disability by the EDSS score 2 years before and after initiation of alemtuzumab treatment

P=.6177



Results


Number of MRI lesions (Gadolinium)
Number of MRI lesions
6
5
4
3
2
1
0
number of lesion before treatment (GD)
number of lesion after treatment (GD)

- Questions?